Temozolomide (TMZ) + Pembrolizumab
Phase 2Active 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glioblastoma
Conditions
Glioblastoma, Glioblastoma, WHO Grade IV
Trial Timeline
Feb 23, 2018 → Dec 1, 2027
NCT ID
NCT03405792About Temozolomide (TMZ) + Pembrolizumab
Temozolomide (TMZ) + Pembrolizumab is a phase 2 stage product being developed by Novocure for Glioblastoma. The current trial status is active. This product is registered under clinical trial identifier NCT03405792. Target conditions include Glioblastoma, Glioblastoma, WHO Grade IV.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03405792 | Phase 2 | Active |
Competing Products
20 competing products in Glioblastoma